TICKERNERD
Menu
AVXLAVXLHealthcare · Biotechnology

AVXL Stock Forecast: Anavex Life Sciences Corp. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$1.30
0.00% on the day

The 1 Wall Street analysts covering Anavex Life Sciences Corp. hold a median 12-month price target of $20 — +1438.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 29 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$121.4M
Ticker Nerd rank
22/ 100
Median analyst target
$20
Analysts covering
1
Revenue$0.0
Operating income$6.8M
Net income$7.8M
Free cash flow−$9.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.4%
1M
−44.9%
YTD
−63.5%
1Y
−83.8%
From 52W high
−83.8%
From 52W low
+4.0%
$1.25
$8.03
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AVXL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Anavex Life Sciences Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 29 Oct 2026
22/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
82
Size
72
Quality
68
Issuance
44
Revisions
25
Volatility
18
Value
18
Accruals
16
Momentum
8

Growth (82): Sales and profits are climbing, and climbing faster than before.

Momentum (8): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AVXL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AVXL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26AVXLHigh $20Median $20Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $20Median $20High $20

The green dot is the last close — the median target sits +1438.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 Mar 2026D. Boral CapitalMaintainsBuy$24
26 Mar 2026D. Boral CapitalMaintainsBuy$24
23 Mar 2026D. Boral CapitalMaintainsBuy—
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
9 Feb 2026D. Boral CapitalMaintainsBuy—
6 Jan 2026D. Boral CapitalMaintainsBuy—
19 Dec 2025D. Boral CapitalMaintainsBuy—
19 Dec 2025HC Wainwright & Co.ReiteratesBuy—
15 Dec 2025D. Boral CapitalMaintainsBuy—
28 Nov 2025HC Wainwright & Co.ReiteratesBuy—
26 Nov 2025D. Boral CapitalMaintainsBuy—
19 Nov 2025HC Wainwright & Co.MaintainsBuy—
14 Nov 2025D. Boral CapitalMaintainsBuy—
29 Oct 2025D. Boral CapitalMaintainsBuy—
24 Oct 2025Jones TradingDowngradeHold—
7 Oct 2025HC Wainwright & Co.ReiteratesBuy—
2 Oct 2025D. Boral CapitalMaintainsBuy—
1 Oct 2025D. Boral CapitalMaintainsBuy—
10 Sept 2025D. Boral CapitalMaintainsBuy—
10 Sept 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

AVXL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

AVXL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Anavex Life Sciences Corp. returned −83.8% against +13.1% for the S&P 500, dividends included.

AVXL vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26AVXLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AVXL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Anavex Life Sciences Corp. (AVXL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.4×

Cheaper than 87% of US stocks

Price / sales
—
Price / book
1.1×

Cheaper than 68% of US stocks

EV / EBITDA
−0.1×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−12.8%

Higher than 35% of US stocks

Return on assets
−9.7%

Higher than 27% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Anavex Life Sciences Corp. (AVXL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Anavex Life Sciences Corp. has a market value of $121.4M and an enterprise value of $3.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$13.0M.

  • Diluted earnings per share, trailing twelve months: $−0.15.

  • Free cash flow in the twelve months to 30 June 2026: −$29.3M.

  • Shares outstanding: 92.7M.

  • Trailing P/E: −2.4×; forward P/E: −2.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Anavex Life Sciences Corp. employs 34 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

AVXL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AVXLAnavex Life Sciences Corp.$121.4M22
OTLKOutlook Therapeutics, Inc.$120.1M4
ARMPArmata Pharmaceuticals, Inc.$119.1M71
FHTXFoghorn Therapeutics, Inc.$122.4M40
NKTXNkarta, Inc.$118.3M43
TLSATiziana Life Sciences Ltd. (Bermuda)$116.1M20
HURATuHURA Biosciences, Inc.$125.1M16

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Anavex Life Sciences Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AVXL news & analysis

Kirby McInerney LLP Alerts Investors Who Acquired Anavex Life Sciences Corp. AVXL Securities Between November 26, 2025 and August 28, 2026 of Pending Lawsuit

GlobeNewsWire · 29 Oct 2026negative

Kirby McInerney LLP announced that investors who acquired Anavex securities between November 26, 2025 and August 28, 2026 may seek lead-plaintiff status in a pending federal securities class action. The stated deadline is November 30, 2026.

Why it matters — The lawsuit and lead-plaintiff deadline are relevant to AVXL investors following legal proceedings involving the company.

Anavex Life Sciences Corp. Investors Seeking Lead Plaintiff Role Have Until November 30th to Contact Bragar Eagel & Squire, P.C.

GlobeNewsWire · 28 Oct 2026negative

Bragar Eagel & Squire, P.C. says investors who suffered losses in Anavex (AVXL) may contact litigation partner Brandon Walker to discuss their options. Investors seeking the lead plaintiff role have until November 30th to contact the firm.

Why it matters — The announcement concerns a legal matter and a deadline that may be relevant to AVXL investors.

AVXL Stockholders Have Rights - If You Lost Money Investing in Anavex Life Sciences Corp. Contact Robbins LLP for Information About Recovering Your Losses

PRNewsWire · 28 Oct 2026negative

Robbins LLP says a class action was filed on behalf of people and entities that acquired Anavex Life Sciences securities during November 26, 2025–August 28, 2026, and is notifying investors of their rights.

Why it matters — The legal action concerns AVXL investors who acquired securities during the specified period.

FAQ

Frequently asked questions about AVXL stock

What is the AVXL stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Anavex Life Sciences Corp. have a median 12-month price target of $20, with estimates ranging from $20 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AVXL stock a buy right now?

Of the 1 analysts covering Anavex Life Sciences Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Anavex Life Sciences Corp. 22 out of 100 across roughly 4,600 US stocks as at 29 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AVXL?

As at 29 Oct 2026, Anavex Life Sciences Corp. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (82 of 100).

Will AVXL stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +1438.5% from the last close, and Ticker Nerd's factor model ranks Anavex Life Sciences Corp. 22 out of 100 as at 29 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AVXL stock forecast for 2030?

No analyst covering Anavex Life Sciences Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVXL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.

How has AVXL stock performed over the past year?

Anavex Life Sciences Corp. returned -83.8% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Anavex Life Sciences Corp. do?

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing oral therapies for central nervous system disorders.

What is the latest news on AVXL?

The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Kirby McInerney LLP Alerts Investors Who Acquired Anavex Life Sciences Corp. AVXL Securities Between November 26, 2025 and August 28, 2026 of Pending Lawsuit". Kirby McInerney LLP announced that investors who acquired Anavex securities between November 26, 2025 and August 28, 2026 may seek lead-plaintiff status in a pending federal securities class action. The stated deadline is November 30, 2026.

Company

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing oral therapies for central nervous system disorders. Its current pipeline targets conditions such as Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other neurodegenerative, neurodevelopmental, and neuropsychiatric diseases. The company’s work centers on precision medicine approaches designed to address high unmet medical needs in brain health, with a primary emphasis on advancing candidate medicines through clinical development. Anavex Life Sciences Corp. operates in the biotechnology sector and serves as a research-driven participant in the global pharmaceutical market, where it contributes to the development of potential treatments for complex neurological diseases.

CEO Dr. Christopher U. Missling M.B.A., M.S., Ph.D. · 34 employees · United States · https://www.anavex.com